|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1992-12-2
|
|
pubmed:abstractText |
The objective of this study was to assess the relationship of different doses of a long-acting bromocriptine preparation (Parlodel LAR) to the degree and duration of PRL suppression. We also measured circulating bromocriptine levels and altered tolerability of the drug.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0300-0664
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
36
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
369-74
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
|
|
pubmed:year |
1992
|
|
pubmed:articleTitle |
Efficacy of a new long-acting injectable form of bromocriptine in hyperprolactinaemic patients.
|
|
pubmed:affiliation |
Division of Endocrinology, Ospedali Riuniti, Bergamo, Italy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|
